As per a recent report in The Lancet, the incidence of prostate cancer is expected to double in India over the next few years. A crucial weapon in averting a severe health catastrophe will be early detection. But before addressing the issue of testing, there’s a knotty ribbon problem to be solved.
Related Posts
Can Cipla make inhaled insulin a successful option for diabetes patients?
Umang Vohra, Global CEO, Cipla. Will Cipla’s big bet work?; image credit: Company. Synopsis Millions of diabetes patients have to…
us shark tank: Selling cut-price generics, Mark Cuban is shaking up US pharma. Can Indian drug makers benefit?
Getty Images Mark Cuban. Synopsis Most of the large Indian pharma companies earn a big chunk of their revenue by…
Once dumped by investors, Orchid Pharma blooms in glory with first novel antibiotic drug
Getty Images Synopsis Orchid Pharma had outlicensed its experimental antibiotic drug to Allecra Therapeutics of Germany. After years of research…
